Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib ± Apatinib Maintenance in Advanced Ovarian Cancer
NCT04229615Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (3 arms), sponsored by Hengrui. Primary endpoints: Incidence of ≥3 grade Treatment-Related Adverse Events and Progression-Free Survival up to 4 years. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT04229615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229615.